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Abstract.
Background: Alzheimer’s disease (AD) is the primary cause of cognitive decline. A growing body of evidence suggests that
AD patients have a higher risk to develop epileptic seizures; however, results are contradictory due to different methodological
approaches of previous studies.
Objective: We aimed to identify the prevalence, semiology, and risk factors of epilepsy in AD using long-term EEG.
Methods: We selected forty-two AD patients and examined them using 24-hour ambulatory EEG. Neurological and epilep-
tological data were collected with retro- and prospective methods. We analyzed the semiology of the identified seizures and
the possible risk factors using logistic regression analysis.
Results: We identified seizures confirmed by EEG in 24%. The majority of the seizures were aware focal (72%) without
any motor activity (55%). We found epileptiform discharges without seizures in 28%. Patients with seizures and only
with epileptic EEG activity showed similar clinical and demographical features. Higher education (OR:1.8) and lower
Addenbrooke Examination Score (OR: 0.9) were identified as risk factors of epilepsy. Increase of 0.1 point in the Verbal-
Language/Orientation-Memory ratio (VLOM) was associated with higher epilepsy risk as well (OR:2.9).
Conclusion: Epilepsy is a frequent comorbidity of AD. Since most of the seizures are aware non-motor focal seizures,
sensitive EEG techniques are required for precise diagnosis of epilepsy. Long-term ambulatory EEG is a safe and well-
tolerated option. Epileptiform EEG in AD signals the presence of concomitant epilepsy. Clinicians have to pay attention to
comorbid epilepsy in dementia patients with high education, with high VLOM ratio and severe stage.
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INTRODUCTION
Major neurocognitive disorders are devastating
conditions leading to progressive cognitive deterio-
ration and affecting approximately 47 million people
worldwide [1]. Expectedly, this number will triple
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of Clinical Neurosciences, 57 Amerikai u´t, 1145-Budapest,
Hungary. Tel.: +36305421019; E-mail: andras.horvath.semmel
weis@gmail.com.
by 2050 [2]. The most common cause of cogni-
tive decline is Alzheimer’s disease (AD) which is
an important mortality factor severely compromising
the quality of life of the elderly [3]. While numer-
ous studies identified important contributing genes,
molecules and factors in the development of AD, we
are still not able to treat or significantly slow down the
progression of cognitive decline. This is why studies
focusing on the possibly modifiable risk factors are
gaining more attention [4]. While the concomitant
ISSN 1387-2877/18/$35.00 © 2018 – IOS Press and the authors. All rights reserved
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cardiovascular disorders and metabolic conditions
are frequently analyzed in AD, the real prevalence
and impact of epilepsy is still unclear [5].
Epilepsy and AD share many similar patterns
including neuropathological hallmarks, neuroimag-
ing findings and molecular changes. The most fre-
quently known protein aggregations of AD such as
the amyloid plaques and tau neurofibrills have been
demonstrated in the samples of mesio-temporal lobe
epilepsy patients (MTLE) as well [6, 7]. Temporal
hypometabolism shown by PET imaging and hip-
pocampal sclerosis revealed by MRI scans are shared
features [8, 9]. The decrease in calbindin-D28 expres-
sion in the dentate gyrus indicating pathological
hyperactivity is a similar finding [10]. Genetically
modifiedanimalmodelsofADfrequentlyhaveepilep-
tic seizures even in their early phase of life [11, 12].
Human prevalence studies on AD-related epileptic
seizures demonstrated highly variable results ranging
between 0.5–64% [5]. However, we cannot convinc-
ingly compare the reported prevalence values due
to the different methodological approaches used in
various studies. Prospective studies and postmortem
histological confirmation of the diagnosis were rare
among investigations reporting about epilepsy preva-
lence in AD [13–16]. Another important obstacle
is that the diagnostic criteria of AD have signifi-
cantly changed over the last decades [17]; hampering
conclusions from the early studies. Additionally,
studies examined AD patients with different sever-
ity of cognitive impairment making problematic the
comparisons of incidence rates. The lack of EEG
recordings in most studies is an additional impor-
tant limiting factor. Based on the current International
League Against Epilepsy (ILAE) guidelines, epilepsy
is diagnosed if the patient suffered two indepen-
dent epileptic seizures or only one but the EEG
shows interictal epileptiform discharges (IEDs) [18].
Therefore, the diagnostic accuracy of any study with-
out adequate EEG recordings is certainly reduced.
While numerous studies [19, 20] used different EEG
techniques and analysis (e.g., directionality of syn-
chronization, resting state source analysis, spectral
and power analysis, spatial coupling, functional con-
nectivity measurements) to identify the biomarkers of
AD (for a thorough review, see [21]), unfortunately,
EEG is barely applied in AD studies focusing on
comorbid epilepsy [5]. Furthermore, analysis of the
semiological features and risk factors of seizures was
conducted only in 3 studies [22–24]. Based on these
results, AD-associated epileptic seizures are non-
motor aware focal seizures occurring predominantly
in advanced disease stages. Because epileptic activity
might have an important role in the pathophysiology
of AD [25, 26], there is a clear need for further and
more detailed studies on the prevalence of epilepsy
in AD [27].
The objective of this study was to examine rigor-
ously selected AD patients by a sensitive EEG method
to analyze the prevalence of epilepsy, the semiology
of epileptic seizures and identify their possible risk
factors.
METHODS
Patient selection
In the framework of the Hungarian National Brain
Research Program, we recruited 42 AD patients (25
women) treated in the Department of Neurology of
the National Institute of Clinical Neurosciences in
Budapest, Hungary. The patients met the revised
diagnostic criteria of the National Institute of Neu-
rological and Communicative Disorders and Stroke
and Alzheimer’s disease and Related Disorders Asso-
ciation (NINCDS–ADRDA) for probable AD [17].
Since we have no access to PET biomarkers and lim-
ited access to CSF biomarker analysis in our country,
we selected the bitemporal, bifrontal, and hippocam-
pal atrophy on the structural MRI as supporting
biomarkers, as they are equally accepted biomark-
ers of AD according to the current guidelines. MRI
acquisition was obtained in every case and images
were analyzed visually by experienced radiologists
and trained physicians independently. Medial tempo-
ral lobe atrophy (MTA) score was applied to support
the diagnosis of AD [28]. MTA analyzes T1 weighted
MRI images through the hippocampus at the level
of the anterior pons and examines three features:
width of the choroid fissure, width of the temporal
horn of the lateral ventricle and the height of the
hippocampus [28]. The score ranges between 1 and
4; atrophy is significant and the presence of AD is
likely if the score ≥2. All known seizure provoking
factors were used as exclusion criteria: antipsychotic,
benzodiazepine, antihistamine or antidepressant ther-
apy in the last month; MRI lesions other than the
typical features of AD including vascular lesions
[29]; alcohol or drug dependency, CNS infection,
head trauma with loss of consciousness, stroke, major
depression, schizophrenia, electroconvulsive therapy,
untreated underactive or overactive thyroid, liver or
kidney failure in the medical history. Because it is
known that epileptic seizures may precede the onset
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of cognitive decline by a few years [30], we excluded
patients with a seizure-history longer than 10 years
prior to the onset of cognitive decline. The patients
underwent proper physical and epilepsy evaluation
including medical, neurological status, epilepsy his-
tory and seizure description, provoking factors, etc.;
routine blood checks including thyroid functions.
Besides demographic markers we recorded the onset
of cognitive decline, the duration of dementia, the
first appearance of seizure-like symptoms, the hand-
edness and education-level of the patients as well as
the use of anti-dementia medication. We obtained
informed consent from each patient. Our research
was authorized by the National Ethic Committee
(024505/2015/OTIG).
Neuropsychology
A neuropsychological testing was performed
in each case by a trained clinician or qualified
neuropsychologist. We selected the Addenbrooke
Cognitive Examination (ACE) for measuring cogni-
tive functions. ACE is a frequently applied bedside
neuropsychological test battery for the diagnostic
evaluation of dementia and mild cognitive impair-
ment. It is highly sensitive (94%) and specific (89%)
for AD [31]. It measures five cognitive domains:
verbal fluency, language, memory, visuo-spatial and
executive-orientation skills. The maximum score is
100; a score less than 82 indicates dementia with 84%
sensitivity and 100% specificity without age and edu-
cation dependency. An important advantage of ACE
is that it contains the Mini-Mental State Examina-
tion (MMSE) score as well. With MMSE, clinicians
can assess the severity of dementia and compare the
results with other studies because this is the most
frequently applied diagnostic test in the evaluation of
cognitive decline [32]. Furthermore, the ACE VLOM
ratio ((Verbal fluency+ Language scores)/ (Orienta-
tion and Memory scores)) can differentiate AD and
frontotemporal dementia [33]; a VLOM ratio >3.2
indicates AD type dementia.
Neurophysiology and prevalence analysis
Each patient had a 24-hour long ambulatory EEG
without video monitoring as an inpatient in our hos-
pital. We used 34 channels and 128 Hz sampling rate
(Micromed Morpheus Polysomnograph, 10–20 elec-
trode placement system). For visual EEG analysis we
used a bipolar montage, 10 microV/mm amplifica-
tion, 70 Hz high pass-, 0.53 Hz low pass-, and 50 Hz
notch filters. We focused on the recognition of IEDs
since their presence together with a previous epileptic
seizure supports the diagnosis of epilepsy [34]. IEDs
were defined as paroxysmal EEG graphoelements
(spikes or sharp waves) of 20–200 ms duration fol-
lowed by slow waves and disrupted background activ-
ity. Two independent, trained neurophysiologists
analyzed the EEGs (Z. Cs., A. H.). One of them was
blinded to the identity of the patients, while the other
one knew the clinical history. A graphoelement was
considered as IED (localized or generalized spikes or
sharp waves; spike-and-wave complexes, ≥3 s rhyth-
mic synchronization) [35], if both raters evaluated it
so. To analyze the sensitivity of ambulatory EEG in
the diagnosis of AD-related epilepsy, we examined
the occurrence of IEDs in the first 30 min of record-
ings (the length of a routine daytime EEG) separately.
The diagnosis of epilepsy was based on the current
ILAE recommendations [18]; two epileptic seizures
with at least 24 hours apart or one unprovoked seizure
with interictal epileptiform activity on the EEG.
Epileptologic data were collected retrospectively
recalled from self or by others and from previous
medical records. Seizure semiology was determined
by three experienced epileptologists (A.SZ., G.B.,
A.K.). The classification of seizures was based on the
current ILAE guidelines; the semiological features
were described accordingly. A seizure with motor
action of at least one limb was considered convul-
sive. A seizure was considered as generalized if the
jerks involved all limbs. An aware focal seizure was
defined as an episode with focal symptoms and pre-
served consciousness, while by definition, during a
focal seizure with impaired awareness disturbance of
consciousness or cognitive distraction of the patient
was recognized.
Risk analysis
We divided the AD patients into three subgroups;
one with epileptic seizures (AD+ES), one with
epileptiform discharges (AD+ED) and another with
no epilepsy (AD+NE). Intergroup differences were
compared using Kruskal-Wallis or independent sam-
ple ANOVA analysis. Since epileptiform potentials
might indicate the presence of epilepsy but the asso-
ciation is not clear in AD, we compared the clinical
and epidemiological data of the AD+ES and AD+ED
using t-tests and Mann-Whitney U test. We applied
IBM SPSS 20 software for statistics.
According to the literature, the level of educa-
tion, the severity of temporal and frontal atrophy, the
AU
TH
OR
 C
OP
Y
1048 A. Horva´th et al. / Epilepsy in AD: An Ambulatory EEG Study
Fig. 1. EEG section from a 24-hour EEG recording of an AD patient. The figure demonstrates the build-up of an epileptic ictal activity in
the left temporal and centro-parietal electrodes (arrow).
onset of cognitive decline and the severity of the dis-
ease represent risk factors for dementia-associated
epilepsy; these features were analyzed as potential
predictors using multivariate logistic regression anal-
ysis. We measured the education level with years
of schooling, the atrophy level with the MTA score
and the disease severity with the ACE score. Since
many studies demonstrated that AD patients have a
high risk for epileptic seizures but reports on other
type of dementias are limited, we hypothetically pro-
posed that the pattern of cognitive decline measured
by ACE indicating Alzheimer-type dementia might
predict the presence of seizures, so we added the
VLOM ratio to the model as well. Confidence inter-
vals (95%), prevalence estimates and point estimates
(Odds-ratio) were calculated by logistic regression.
RESULTS
Demographic and prevalence data
In twenty patients out of the forty-two (48%) we
did not detect epileptiform activity or seizures on the
EEG, neither found any data on seizures in the past
medical history. In twelve patients (28%) we found
epileptiform discharges on the EEG but there were
no seizures in the history. We diagnosed epileptic
seizures in ten patients out of forty-two (24%). In two
patients of these ten, we recorded electric ictal pat-
tern two times during the recording period (Fig. 1).
In four patients of ten, two or more seizures were
identified in the medical history, while in six patients
only one (95%CI: 0.99–2.61). In 8 of the 10 AD
patients with clinically identified seizures, the ambu-
latory EEG showed IEDs as well (95%CI: 0.5–1.1)
(Fig. 2). Altogether, we detected epileptiform activity
in 48% of our AD patients (8 patients from AD+ES
group and 12 patients of AD+ED group).
In the first 30 min the EEG contained IEDs in only
three patients out of those twenty who had either
seizures or IEDs in the full length recording (8 with
seizures+ interictal pattern and 12 with epileptiform
discharges); therefore, if we suppose that the first
30 min of the ambulatory recording corresponds to
a routine EEG, than the calculated sensitivity value
for routine EEG in this study is only 15% (95%CI:
–0.02–0.32).
We collected the major demographic and clini-
cal features of the three analyzed groups: 1) AD
patients without seizures or subclinical epilepti-
form discharges (AD+NE; n = 20), 2) AD patients
with epileptic seizures (AD+ES; n = 10), and 3) AD
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Fig. 2. EEG section from a 24-hour EEG recording of the same AD patient than in Fig. 1. There is an interictal sharp wave in the left
temporal region with phase inversion at F7 electrode (circles).
patients without seizures but with epileptiform dis-
charges (AD+ED; n = 12). Data were compared with
Kruskal-Wallis and independent ANOVA analysis.
The three groups did not differ significantly in gender
and age; however, they showed differences in several
clinical features as it is demonstrated in Table 1.
To analyze the value of EEG positivity in AD,
we compared the AD+ED and the AD+ES groups
with univariate analysis. The differences between the
AD+ES and AD+ED groups were non-significant for
age (95%CI: –4.43–9.065; p: 0.482), for the age of
onset (95%CI: –7.78–7.44; p: 0.964), for education
level (95%CI: –0.671–1.83; p: 0.343), for MTA score
(95%CI: –0.273–0.673; p: 0.388), for sex (p: 0.353),
for handedness (p: 0.658), or for memantine therapy
(p: 0.844). The only marginal difference was the dura-
tion of dementia (95%CI: 0.16–4.8, p: 0.037), where
patients with seizures showed longer duration.
Risk factors for epileptic activity revealed by
logistic regression analysis
Since the AD+ED and the AD+ES groups showed
many similarities, in order to increase the statistical
power, we combined the AD+ES and AD+ED groups
(AD+ES/ED, altogether 22 patients) and compared
the data to the AD+NE group (20 patients). In a logis-
tic regression model, we analyzed which potential
Table 1
Demographic and clinical features of AD patients with epileptic seizures (AD+ES), with epileptiform discharges (AD+ED) and without
epileptic seizures or EEG positivity (AD+NE) and the results of statistical comparisons
Parameter AD+NE AD+ES AD+ED Results of ANOVA
and Kruskal-Wallis
Number of patients 20 10 12 –
Gender (% of females) 55% 70% 60% 0.94
Memantine therapy (% of patients) 15% 20% 17% 0.117
Cholinesterase inhibitor therapy (% of patients) 100% 100% 100% 1
Age 79.4 ± 7.4 75.9 ± 4.7 73.6 ± 9.3 0.110
Handedness (% of right handed patients) 86% 90% 84% 0.209
MTA score 2.65 ± 0.67 3.2 ± 0.78 3 ± 0.6 *0.02
Age at the onset of dementia 74.4 ± 5.9 68.5 ± 4.1 68.6 ± 10.9 *0.049
Duration of dementia 4.9 ± 2.9 7.4 ± 1.7 4.91 ± 3.14 *0.049
Education (y) 11.6 ± 2.5 16.5 ± 1.1 15.9 ± 1.6 *<0.001
ACE score 67.4 ± 9.4 38.4 ± 15.3 44.5 ± 7.4 *<0.001
VLOM ratio 3.3 ± 0.8 3.5 ± 0.2 3.5 ± 0.1 *0.008
* indicates statistical significance between the three analyzed groups. MRI supported the diagnosis of AD in every case based on the MTA
score. MTA, medial temporal lobe atrophy score; ACE, Addenbrooke Cognitive Examination; VLOM, verbal-language/orientation-memory
ratio.
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Table 2
Results of logistic regression analysis demonstrating Odds-ratios
and confidence intervals
Variable Odds-ratio 95% confidence interval
Age (y) 0.973 0.514–1.839
Onset of dementia (age) 0.991 0.48–2.047
Education (y) 1.801 0.875–3.706
MTA score 1.095 0.026–45.56
ACE score 0.874 0.761–1.003
VLOM ratio 26.77 0.036–20169
* indicates significant differences. ACE, Addenbrooke Cognitive
Examination; MTA, medial temporal lobe atrophy score; VLOM,
verbal-language/memory-orientation ratio.
factors increase the risk of developing epileptic activ-
ity. We found that patients with higher education
(odds ratio for 1 year higher education: 1.8), higher
ACE scores (odds ratio for 1 point decrease: 0.87)
and increased VLOM ratios (odds ratio: 2.68 for
0.1 point) have an increased chance for developing
epileptic activity (Table 2).
Seizure semiology
We analyzed the semiologic features of eighteen
seizures of ten AD patients based on the auto-, het-
eroanamnesis and previous medical reports (Table 3).
We detected generalized tonic-clonic seizures in 11%
and focal onset seizures with impaired awareness in
72%. Fifty-five percent of seizures were non-motor.
DISCUSSION
Growing body of evidence suggests that AD
patients have a high risk to develop epileptic seizures
[5]. However, the real prevalence of epilepsy is not
known due to the methodological differences of
human prevalence studies and to the limited number
of studies analyzing the risk factors of AD-related
epileptic seizures.
Most of the previous studies used retrospective
analyses from hospital based or national databanks
[36–40]. The major limitation of these studies is the
difficulty to prove the diagnosis of epilepsy or AD
in questionable cases. The comparison of our results
with previous data is also hard, due to the changes
in the diagnostic guidelines and criteria of AD [17].
However, most prevalence studies found elevated risk
for epileptic seizures [5] being in line with our cur-
rent results where 24% of AD patients have epileptic
seizures and another 28% shows epileptic activity on
the EEG.
EEG is essential in the diagnosis of epilepsy
according to the existing guidelines [18]. Long-
term EEG recordings including sleep may offer an
importantly higher diagnostic yield [41], as we have
reported earlier [42]. Our current research demon-
strates that 24-hour ambulatory EEG is a safe and
well tolerated method for the diagnosis of AD-related
epileptic activity since all recordings were performed
without any complications. In the literature only one
study applied EEG using mostly only routine 30 min
recordings and a few serial EEGs [24]. The current
study also reinforces that short EEGs have a low diag-
nostic yield, as we found only 15% sensitivity for
IEDs of the first 30 min EEG which is the average
length of a routine EEG recording. It demonstrates
an evidence for the limitation of brief EEG monitor-
ing in the clinical assessment of dementia associated
epilepsy. The benefit of extension the length of EEG
over 24 hours is questionable in AD; however, our
previous results indicated that the sensitivity of EEG
reaches a plateau after 8-hour sleep EEG [42].
The remarkable similarity of demographic and
clinical data of the patients with epileptic seizures
(AD+ES) and the patients with epileptiform dis-
charges only (AD+ED) is a very important finding.
There are only limited number of studies investigat-
ing the prevalence and importance of epileptiform
Table 3
The semiology of epileptic seizures in AD patients. Seizures were focal with impaired awareness
in 72% and in 55% there was no motor activity seen
Type of seizure Number of Semiology features
seizures
Aware focal
Non-motor 1 Jamais vu/de´ja vu
Motor 1 Clonization of right upper limb
Impaired awareness focal
Non-motor 8 Speech arrest (1), amnestic episode (4), confusion (3)
Motor 5 Bilateral limb jerks (3), Right upper limb clonus (2)
Generalized
Atonic 1 Atonia
Tonic-clonic 2 Generalized tonic-clonic
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potentials in AD with ambiguous prevalence data.
Liedorp and his colleagues analyzed the data of
30 min long daytime EEGs of 1674 AD patients and
found subclinical epileptiform activity only in 3% of
the sample [43]. In Vossel’s study involving serial
routine EEG recordings, the prevalence of epilep-
tiform activity was 6% [24]. Our finding of 48%
epileptiform activity rate is significantly higher. The
explanation might be that we analyzed 24 hours long
EEGs including whole night sleep recordings. It has
been clearly shown in several epilepsy studies that
epileptiform activity increases during sleep. We have
reported similar findings in AD patients [42]. In the
study of Vossel et al., the routine EEG was nor-
mal in 60% of those AD patients who had clinically
overt epileptic seizures, while sleep deprived serial
EEGs have shown epileptiform discharges in 84% in
those patients [24]. This is supported by another study
of Vossel’s group about the temporal distribution of
epileptiform activity in AD showing that epileptic
activity occurs almost exclusively (90%) during sleep
[26]. They found epileptiform discharges in 42% of
AD patients being in line with our results. Addition-
ally, those patients suffered 2.5-times faster decline
in their yearly measured MMSE scores than patients
with no epileptic activity suggesting the significant
importance of epileptiform activity in the progression
of AD.
Our results show strong link between the
patients with definitive seizures (AD+ES) and with
epileptiform activity (AD+ED). Based on the over-
lapping clinical, demographical features and on the
knowledge from previous studies suggesting that
epileptiform discharges are associated with acceler-
ated cognitive decline, we propose that the AD+ED
patient group represents incidental new epilepsy
cases. While further studies are required to reinforce
these findings, we suggest that we might consider
thinking about AD patients with epileptiform EEG
as patients with epilepsy.
A further point is analysis of seizure semiology
which has been performed in only four reports in the
literature. One of them was a prevalence study [24],
while the others examined dementia patients with
known epilepsy diagnosis [38, 44, 45]. These three
studies analyzed inhomogeneous patient groups,
where out of the altogether 167 patients only 108
had AD. The four studies reported generalized tonic-
clonic seizures in 32.5%, focal seizures with impaired
consciousness in 52.25% and aware focal seizures in
15%. Based on the literature, non-motor seizures with
impaired awareness are typical among AD patients.
In the most detailed study, the common symptoms
were confusion, disturbance of consciousness, jamais
vu, de´ja` vu, and visceral sensations [24]; all typical in
temporal lobe epilepsy [46]. In our study, generalized
tonic-clonic seizures were less frequent (11%), while
we found focal seizures with impaired consciousness
in (72%) mostly without motor activity; being in line
with previous findings [24, 38, 44, 45].
The dominance of focal non-motor seizures with
impaired awareness raises an important clinical
consideration. AD patients frequently show daily
changes in mood, in cognitive performance and in
communication skills. In light of the present study,
this variability might at least partially be explained
by epileptic disturbances. Video-EEG monitoring or
ultra-long-term EEG recordings are needed to clarify
the epileptic background of these phenomena. We can
conclude that it is challenging to recognize the symp-
toms of non-motor focal seizures in AD and without
searching for them, epilepsy may easily remain hid-
den [47, 48].
Early studies regarding the risk factors of AD-
related epileptic seizures were not conclusive [14,
23]. Amatniek et al. found that more severe disease
stage (relative risk: 4.15), early onset of cognitive
decline (relative risk: 0.89/year), African American
race (relative risk: 7.35) and epileptiform EEG sig-
nals (relative risk: 73.36) were important risk factors
[22]. Early disease onset as a risk factor has also been
shown [36, 49]. Volicer et al. demonstrated the impact
of severe stage of AD [50], while in other studies the
incidence of seizures was independent from the dis-
ease stage [45, 51]. Vossel and his coworkers reported
that seizures were present also in less advanced dis-
ease, even in mild cognitive impairment [24]. The
same study demonstrated that higher education is also
a risk factor. To our best knowledge, the neuropsycho-
logical pattern of cognitive dysfunction represented
in our study by the VLOM ratio has been not analyzed
in previous reports.
The early onset of cognitive decline is a consistent
risk factor of epilepsy in the literature. A possible
explanation is that early onset might be related to a
genetic cause, and it is known that in these forms,
epileptic seizures are significantly more frequent
[13]. In our study this factor was not statistically sig-
nificant, however, in line with some previous reports,
the severe disease state was a prominent risk factor
(odds ratio: 0.874 for 1 point ACE score increase)
[22, 50]. Regression analysis has not been applied
in previous publications, so it might be possible that
the leading risk factor is the severe disease stage and
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patients with earlier onset reach the advanced disease
state sooner. However, seizures were reported in the
preclinical and mild stages as well [24, 44, 47]. In
the future, we aim to answer this question by studies
involving patients with mild AD and mild cognitive
impairment.
To our best knowledge, there is no previous study
analyzing the neuropsychological pattern as a seizure
predicting factor in dementia. We found that the ele-
vated VLOM ratio has a 26.77 odds ratio for epilepsy
in AD. It might be possible that the increased VLOM
ratio is connected to the more severe disease stage,
so the typical neuropsychological pattern became
more prominent during the development of cognitive
decline. However, it is also possible that AD is a pre-
disposing disease for epilepsy compared to other neu-
rocognitive disorders. Therefore, the Alzheimer-like
VLOM ratio could be a good indicator for physicians
to search for concomitant epilepsy, especially if we
consider that 0.1 point increase in the VLOM ratio is
associated to 2.67 odds ratio for developing seizures.
Further studies analyzing the occurrence of epilepsy
in AD patients with typical and atypical VLOM pat-
tern from the early phase of cognitive deterioration
are needed to reinforce these findings.
Epileptiform EEG is a well-known indicator of
seizure activity in epileptology. In our study AD
patients with epileptiform potentials showed seizures
in 40% (eight AD patients with seizures and EDs
out of twenty AD patients (eight AD patients with
seizures and EDs+twelve with EDs only), while just
8% had no epileptiform discharges (two AD patients
with seizures and without IEDs out of the twenty-two
AD patients (two AD patients with seizures and with-
out IEDs+twenty patients without IEDs or seizures).
Thus, we confirmed the findings of Amatniek et al. in
AD [22]: epileptiform EEG indicates well the pres-
ence of seizures in AD.
The higher education as a risk factor (odds ratio:
1.8) is curious, however, it is consistent with the
results of Vossel et al. [24]. It seems feasible that
patients with higher education report their symp-
toms more accurately. However, it has also been
consistently illustrated that AD patients with higher
education present faster cognitive decline [52, 53].
Cognitive reserve hypothesis could be a possible
explanation, so higher educated patients are able to
compensate the cognitive loss for a longer period,
so at the moment of the diagnosis, the disease will
terminate in a shorter time [53].
Amyloid is an evolutionary preserved molecule
having a crucial role in memory and learning
functions [54]. Theoretically, it is possible that higher
cognitive functioning might augment the amyloid
burden. Amyloid has an epileptogenic potential [55]
and vice versa, epileptic activity increases the amy-
loid deposition via the hyperexcitation [25]. Because
the clearance mechanisms are impaired in AD, amy-
loid accumulation might lead to frequent epileptic
activity, which in turn, might accelerate the progres-
sion of the disease in highly educated AD patients.
Animal models [25] and human studies support this
mechanism [26]. Thus, concomitant epilepsy might
be an explanation both for the educational risk of
seizures and for the education as a modifying factor
in the progression. However, in our sample patients
with epilepsy showed earlier cognitive decline and
higher education seeming to be contradictory, espe-
cially if we consider that the average age for the onset
of dementia (∼69) is a relatively early age in most of
the dementia populations. The inconsistency might be
explainable with the clinical sample oversampling the
care-recipients. Population-based studies are clearly
more representative; however, to define a homoge-
nous AD sample and to exclude the effect of applied
medication on the epileptic threshold, we had to use
all of the available clinical data. Thus, we have to
avoid generalizations and have to emphasize that the
higher education is still a questionable risk factor for
AD-related epilepsy. Further prospective longitudi-
nal neurophysiologic studies are needed to answer
this question.
Conclusions
We found epileptic seizures in a quarter of AD
patients and epileptiform activity in 48% of them;
therefore, we can conclude that epilepsy repre-
sents an important comorbidity of AD. Patients with
seizures and patients with epileptiform discharges
show similar clinical characteristics suggesting that
EEG positivity in AD might represent new inciden-
tally diagnosed epilepsy cases. The typical seizures
are non-motor focal seizures which are hard to rec-
ognize without the application of a sensitive EEG
technique. This might be one of the reasons why
seizures and epilepsy are underdiagnosed in AD.
The 24-hour ambulatory EEG is a safe tool to
increase diagnostic accuracy of epilepsy in AD.
Patients with higher education, with AD-type neu-
ropsychological pattern (typical VLOM ratio) and
in a more severe disease stage have a higher chance
to develop epileptic seizures and epileptiform activ-
ity. Thus, ACE score and VLOM ratio represent a
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useful clinical tool to identify patients with high
risk for epilepsy. Once epilepsy is diagnosed in this
patient group antiepileptic drugs might be considered
as a promising new therapeutic approach. However,
further studies are needed to measure the usefulness
of antiepileptic drugs in AD and additional preva-
lence studies are necessary to examine the occurrence
of seizures in the early or prodromal phases of AD.
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